bioprognos

HRN: _____

ID Card: _____

OncoOVARIAN Dx - Order Form

Biochemistry

General:	☒ Creatinine	☒ ASAT	☒ ALAT
	☒ GGT	☒ Total Bilirubin	
Tumor Markers:	☒ AFP	☒ β-hCG	☒ CA 19.9
	☒ CA 125	☒ CEA	☒ HE4

Anamnesis

Personal Data

Age (years): _____

Menopausal Status

Menopausal:	☐ Pre	☐ Post (less 1year)	☐ Post (more 1 year)
	☐ Unknown		

Comorbidities

Ascites:	☐ Yes	☐ No	☐ Unknown
Cholestasis:	☐ Yes	☐ No	☐ Unknown
Chronic Liver Disease:	☐ Yes	☐ No	☐ Unknown
Jaundice:	☐ Yes	☐ No	☐ Unknown
Metrorrhagia:	☐ Yes	☐ No	☐ Unknown
Pancreatitis:	☐ Yes	☐ No	☐ Unknown
Pericardial/Pleural Effusions:	☐ Yes	☐ No	☐ Unknown
Renal Failure:	☐ Yes	☐ No	☐ Unknown

Order Information

Ordered by: _____ Signature: _____

Order Date: _____

Disclaimer

According to Annex VII of Medical Device Directive 93/42/EEC, Class I, Rule 12, OncoOVARIAN Dx is a non-invasive blood test useful to suggest a possible diagnosis in women with suspected malignancy in the ovarians, reduce inappropriate diagnostic tests, days of hospitalization, as well as morbidity. It is specially designed for women with previous image findings suspicious of Ovarian Cancer that should be biopsied to verify malignancy.

OncoOVARIAN Dx is based in a panel consisting of 6 serum Tumor Markers (AFP, β-hCG, CA 19.9, CA 125, CEA and HE4), as well as clinical data to obtain the best performance (Sensitivity of 93.8% and Specificity of 94.4%), by reducing the number of false positives generated by benign comorbidities and other well-known causes.

Bioprognos SL
Benet Mateu, 40 - 08034 Barcelona (Spain)
Email: info@bioprognos.com
Website: www.bioprognos.com

V.4 Rev.001

CE